SEARCH:   Advanced

Blood, 15 October 2004, Vol. 104, No. 8, pp. 2269-2271. Prepublished online as a Blood First Edition Paper on May 27, 2004; DOI 10.1182/blood-2004-03-1091. This Article Full Text (PDF) All Versions of this Article: 2004-03-1091v1 104/8/2269    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kaufmann, H. Articles by Drach, J. Search for Related Content PubMed PubMed Citation Articles by Kaufmann, H. Articles by Drach, J. Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted March 23, 2004 Accepted May 10, 2004 Anti-tumor activity of rituximab plus thalidomide in patients with relapsed/refractory mantle cell lymphoma Hannes Kaufmann, Markus Raderer, Stefan Woehrer, Andreas Puespoek, Alexander Bankier, Christoph Zielinski, Andreas Chott, and Johannes Drach* Department of Medicine I, Clinical Division of Oncology, University Hospital Vienna, Vienna, Austria Department of Medicine IV, University Hospital Vienna, Vienna, Austria Department of Radiology, University Hospital Vienna, Vienna, Austria Department of Pathology, University Hospital Vierna, Vienna, Austria * Corresponding author; email: johannes.drach{at}meduniwien.ac.at. We evaluated a treatment strategy targeting both lymphoma cells (by rituximab) and the microenvironment (by thalidomide) in 16 patients with relapsed/refractory mantle cell lymphoma (MCL). Rituximab was administered at 375 mg/m2 for four weekly doses concomitantly with thalidomide (200 mg daily, with a dose increment to 400 mg on day 15), which was continued as maintenance therapy until progression/relapse. Thirteen patients (81%) experienced an objective response, with 5 complete responders (31%). Median progression-free survival (PFS) was 20.4 months (95% CI, 17.3 to 23.6), and estimated 3-year survival was 75%. In patients achieving a complete response, PFS after rituximab plus thalidomide was longer than PFS after the preceding chemotherapy. Severe adverse events included two thromboembolic events and one grade IV neutropenia associated with thalidomide. Our results suggest that rituximab plus thalidomide has marked anti-tumor activity in relapsed/refractory MCL and a low toxicity profile, which warrants further evaluation in MCL. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. A. Chanan-Khan and B. D. Cheson Lenalidomide for the Treatment of B-Cell Malignancies J. Clin. Oncol., March 20, 2008; 26(9): 1544 - 1552. [Abstract] [Full Text] [PDF] B. S. Kahl New Therapeutic Strategies for Mantle Cell Lymphoma ASCO Educational Book, January 1, 2008; 2008(1): 392 - 397. [Abstract] [Full Text] [PDF] D. J. Straus How I Treat Mantle Cell Lymphoma J. Oncol. Pract, September 1, 2007; 3(5): 281 - 282. [Full Text] [PDF] M. Wang, L. Zhang, X. Han, J. Yang, J. Qian, S. Hong, F. Samaniego, J. Romaguera, and Q. Yi Atiprimod inhibits the growth of mantle cell lymphoma in vitro and in vivo and induces apoptosis via activating the mitochondrial pathways Blood, June 15, 2007; 109(12): 5455 - 5462. [Abstract] [Full Text] [PDF] T. E. Witzig Current Treatment Approaches for Mantle-Cell Lymphoma J. Clin. Oncol., September 10, 2005; 23(26): 6409 - 6414. [Abstract] [Full Text] [PDF] D. G. Maloney Immunotherapy for Non-Hodgkin's Lymphoma: Monoclonal Antibodies and Vaccines J. Clin. Oncol., September 10, 2005; 23(26): 6421 - 6428. [Abstract] [Full Text] [PDF]

	Copyright © 2004 by American Society of Hematology         Online ISSN: 1528-0020